[go: up one dir, main page]

PL2895477T3 - Pochodne pirazolokarboksyamidu jako modulatory taar do stosowania w leczeniu kilku zaburzeń, takich jak depresja, cukrzyca i choroba parkinsona - Google Patents

Pochodne pirazolokarboksyamidu jako modulatory taar do stosowania w leczeniu kilku zaburzeń, takich jak depresja, cukrzyca i choroba parkinsona

Info

Publication number
PL2895477T3
PL2895477T3 PL13759754T PL13759754T PL2895477T3 PL 2895477 T3 PL2895477 T3 PL 2895477T3 PL 13759754 T PL13759754 T PL 13759754T PL 13759754 T PL13759754 T PL 13759754T PL 2895477 T3 PL2895477 T3 PL 2895477T3
Authority
PL
Poland
Prior art keywords
parkinson
diabetes
depression
disease
treatment
Prior art date
Application number
PL13759754T
Other languages
English (en)
Inventor
Guido Galley
Roger Norcross
Philippe Pflieger
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL2895477T3 publication Critical patent/PL2895477T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
PL13759754T 2012-09-14 2013-09-11 Pochodne pirazolokarboksyamidu jako modulatory taar do stosowania w leczeniu kilku zaburzeń, takich jak depresja, cukrzyca i choroba parkinsona PL2895477T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12184360 2012-09-14
PCT/EP2013/068769 WO2014041007A1 (en) 2012-09-14 2013-09-11 Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease
EP13759754.8A EP2895477B1 (en) 2012-09-14 2013-09-11 Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease.

Publications (1)

Publication Number Publication Date
PL2895477T3 true PL2895477T3 (pl) 2018-03-30

Family

ID=47044779

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13759754T PL2895477T3 (pl) 2012-09-14 2013-09-11 Pochodne pirazolokarboksyamidu jako modulatory taar do stosowania w leczeniu kilku zaburzeń, takich jak depresja, cukrzyca i choroba parkinsona

Country Status (35)

Country Link
US (1) US9487501B2 (pl)
EP (1) EP2895477B1 (pl)
JP (2) JP2015531782A (pl)
KR (1) KR101706486B1 (pl)
CN (2) CN104619700A (pl)
AR (1) AR092537A1 (pl)
AU (1) AU2013314388B2 (pl)
BR (1) BR112015004511B1 (pl)
CA (1) CA2882821C (pl)
CL (1) CL2015000580A1 (pl)
CR (1) CR20150087A (pl)
DK (1) DK2895477T3 (pl)
EA (1) EA026062B1 (pl)
ES (1) ES2654653T3 (pl)
HK (2) HK1206720A1 (pl)
HR (1) HRP20171981T1 (pl)
HU (1) HUE037689T2 (pl)
IL (1) IL237332B (pl)
LT (1) LT2895477T (pl)
MA (1) MA37944B2 (pl)
MX (1) MX363362B (pl)
MY (1) MY178667A (pl)
NO (1) NO2895477T3 (pl)
NZ (1) NZ705154A (pl)
PE (1) PE20150735A1 (pl)
PH (1) PH12015500489A1 (pl)
PL (1) PL2895477T3 (pl)
PT (1) PT2895477T (pl)
RS (1) RS56747B1 (pl)
SG (1) SG11201501958QA (pl)
SI (1) SI2895477T1 (pl)
TW (1) TWI610926B (pl)
UA (1) UA113776C2 (pl)
WO (1) WO2014041007A1 (pl)
ZA (1) ZA201501126B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017103943A (ru) 2014-07-30 2018-08-28 Ф. Хоффманн-Ля Рош Аг Производные 6-амино-5,6,7,8-тетрагидронафтален-2-ила или 3-аминохроман-7-ила в качестве модуляторов taar
PE20181446A1 (es) * 2016-03-17 2018-09-12 Hoffmann La Roche Derivados de 5-etil-4-metil-pirazol-3-carboxamida con actividad como de taar
AU2017378487B2 (en) * 2016-12-15 2022-03-31 The Regents Of The University Of California Compositions and methods for treating cancer
MA55594A (fr) 2019-04-09 2022-02-16 Hoffmann La Roche Composés hexahydro-1h-pyrazino[1,2-a]pyrazine pour le traitement d'une maladie auto-immune
CN117120427A (zh) * 2021-06-18 2023-11-24 上海拓界生物医药科技有限公司 一种malt1抑制剂及其制备方法和用途
CN116236478A (zh) * 2022-12-27 2023-06-09 浙江大学 芳香杂环甲酰胺类化合物的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
WO2012063896A1 (ja) * 2010-11-11 2012-05-18 第一三共株式会社 新規ピラゾールアミド誘導体
US9073911B2 (en) 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) * 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives

Also Published As

Publication number Publication date
IL237332B (en) 2018-07-31
EA201590454A1 (ru) 2015-09-30
JP2015531782A (ja) 2015-11-05
PH12015500489B1 (en) 2015-04-20
HK1252981A1 (zh) 2019-06-06
CA2882821C (en) 2018-05-22
CN107903251A (zh) 2018-04-13
MA37944A1 (fr) 2016-04-29
BR112015004511A2 (pt) 2017-07-04
US20150218131A1 (en) 2015-08-06
MY178667A (en) 2020-10-20
NO2895477T3 (pl) 2018-03-31
HK1206720A1 (en) 2016-01-15
HUE037689T2 (hu) 2018-09-28
EP2895477A1 (en) 2015-07-22
HRP20171981T1 (hr) 2018-02-09
BR112015004511A8 (pt) 2021-11-03
EA026062B1 (ru) 2017-02-28
MX363362B (es) 2019-03-21
MA37944B2 (fr) 2017-10-31
BR112015004511B1 (pt) 2022-08-02
DK2895477T3 (en) 2018-01-15
MX2015002900A (es) 2015-06-03
IL237332A0 (en) 2015-04-30
US9487501B2 (en) 2016-11-08
LT2895477T (lt) 2018-01-25
CA2882821A1 (en) 2014-03-20
KR101706486B1 (ko) 2017-02-13
PE20150735A1 (es) 2015-05-17
EP2895477B1 (en) 2017-11-01
TWI610926B (zh) 2018-01-11
NZ705154A (en) 2018-03-23
AU2013314388B2 (en) 2016-07-14
TW201425308A (zh) 2014-07-01
CN104619700A (zh) 2015-05-13
RS56747B1 (sr) 2018-03-30
ES2654653T3 (es) 2018-02-14
WO2014041007A1 (en) 2014-03-20
AU2013314388A1 (en) 2015-03-05
PT2895477T (pt) 2017-12-29
JP6529998B2 (ja) 2019-06-12
SI2895477T1 (en) 2018-02-28
CR20150087A (es) 2015-04-06
UA113776C2 (xx) 2017-03-10
ZA201501126B (en) 2016-01-27
SG11201501958QA (en) 2015-04-29
KR20150054947A (ko) 2015-05-20
PH12015500489A1 (en) 2015-04-20
JP2017122103A (ja) 2017-07-13
CL2015000580A1 (es) 2015-07-10
AR092537A1 (es) 2015-04-22

Similar Documents

Publication Publication Date Title
HK1211231A1 (en) Exendin-4 derivatives
MX363118B (es) Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
PL2968218T3 (pl) Skojarzenie do leczenia choroby parkinsona
HK1211525A1 (en) Laquinimod and pridopidine for treating neurodegenerative disorders
IL238027A0 (en) 2-phenyl-5-heterocyclyl-tetrahydro-h2-pyran-3-amine compounds for use in the treatment of diabetes and related disorders
GB201105137D0 (en) Therapeutic molecules for use in the suppression of Parkinson's disease
HUE061596T2 (hu) Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
IL237743A0 (en) A combination of rasagiline and pridofidine for the treatment of neurodegenerative diseases, and specifically for the treatment of Huntington's disease
CA2871774C (en) Use of n-acetylcysteine amide in the treatment of disease and injury
ZA201406916B (en) New therapeutic approaches for treating parkinson's disease
IL237332A0 (en) Pyrazole carboxamide derivatives as taar modulators for use in the treatment of serious diseases such as depression, diabetes and Parkinson's disease
SI2739615T1 (sl) Fenil-3-aza-biciklo(3.1.0)heks-3-il-metanoni in njihova uporaba kot zdravilo
IL240949B (en) Aqueous pharmaceutical formulation for use in the treatment of type 1 or type 2 juvenile diabetes
PT3302454T (pt) Composições para utilização no tratamento da doença de parkinson e distúrbios associados
IL274203A (en) A pharmaceutical solution containing dopamine for use in the treatment of Parkinson's disease
EP2968222A4 (en) METHOD, COMPOSITIONS AND DEVICES FOR TREATING MOTOR DISTURBANCES AND DEPRESSION SYMPTOMS RELATED TO MORBUS PARKINSON
EP3162377A4 (en) Use of -asarone in preparing drugs for preventing and treating alzheimer's disease
UA112981C2 (uk) Варіант людського gdnf
WO2014187964A3 (en) Novel treatment of metabolic diseases
WO2012004416A3 (en) Treatment of a disease associated with retinal degenerative disorder
TH1501001422A (th) อนุพันธ์ไพราโซลคาร์บอกซาไมด์ในฐานะ taar โมดูเลเตอร์สำหรับใช้ในการรักษา ความผิดปกติหลายชนิดอย่างเช่นภาวะซึมเศร้า, เบาหวาน และโรคพาร์กินสัน
HK40097673A (zh) ANAVEX2-73的对映体及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途
IL241397A0 (en) Preparations and devices for treating the symptoms of Parkinson's disease
HK1215375A1 (zh) 阿克曼氏菌用於治療代謝病症的用途
WO2013114403A8 (en) Substituted 4,5-dihydro-2h-benzo[e]indazole-9-carboxylates for the treatment of diabetes and related disorders